Ensysce Biosciences, Inc. (ENSC)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-15) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-30) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-14) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-13) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-13) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-10) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-12) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-14) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-13) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-15) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-09) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-11) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statement of Operations | ||
| Consolidated Statement of Changes In Stockholders' Equity | ||
| Consolidated Statements of Changes In Stockholders' Deficit | — |
|
| Consolidated Statements of Changes In Stockholders' Equity (deficit) | ||
| Consolidated Statement of Cash Flows | ||
| Notes | ||
| Accrued Expenses and Other Liabilities | ||
| Basis of Presentation | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Income Taxes | — |
|
| Insider Trading Arrangements | — |
|
| Insider Trading Policies and Procedures | — |
|
| Notes Payable | ||
| Organization and Principal Activities | ||
| Other Assets | ||
| Prepaid Expenses and Other Current Assets | ||
| Related Parties | ||
| Stock-based Compensation | ||
| Stockholders Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||